|
Volumn 342, Issue 6156, 2013, Pages 318-320
|
Path to treat rett syndrome
|
Author keywords
[No Author keywords available]
|
Indexed keywords
4 AMINOBUTYRIC ACID RECEPTOR;
ETHYLNITROSOUREA;
FLUINDOSTATIN;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
METHYL CPG BINDING PROTEIN 2;
MEVINOLIN;
SOMATOMEDIN C;
CHOLESTEROL;
DISABILITY;
DISEASE CONTROL;
NERVOUS SYSTEM;
RESEARCH;
CHOLESTEROL METABOLISM;
CHOLESTEROL SYNTHESIS;
CLINICAL TRIAL (TOPIC);
GENOTYPE PHENOTYPE CORRELATION;
HUMAN;
LIFESPAN;
MOTOR DYSFUNCTION;
MOTOR PERFORMANCE;
MUSCLE HYPOTONIA;
MUTAGENESIS;
NONHUMAN;
OBESITY;
PHENOTYPE;
PRIORITY JOURNAL;
RETT SYNDROME;
REVIEW;
STEM CELL TRANSPLANTATION;
X CHROMOSOME DOMINANT DISORDER;
X CHROMOSOME INACTIVATION;
ANIMAL;
FEMALE;
GENETICS;
MALE;
METABOLISM;
MUTATION;
NOTE;
ANIMALS;
CHOLESTEROL;
FEMALE;
MALE;
METHYL-CPG-BINDING PROTEIN 2;
MUTATION;
RETT SYNDROME;
|
EID: 84885698307
PISSN: 00368075
EISSN: 10959203
Source Type: Journal
DOI: 10.1126/science.1245657 Document Type: Review |
Times cited : (5)
|
References (16)
|